Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nutt

Showing results (631-640 of 790) with videos related to

Pageof 79
Sort By:
Human Brain Mapping|April 9, 2025
The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic StateClayton R Coleman, Kenneth Shinozuka, Robert Tromm, et al.
Drug and Alcohol Dependence|September 7, 2001
beta-carboline binding to imidazoline receptorsS M Husbands, R A Glennon, S Gorgerat, et al.
Addiction Biology|January 7, 2016
The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient settingF D Law, J E Bailey, D S Allen, et al.
The American Journal of Psychiatry|January 1, 1997
Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjectsD T George, C Benkelfat, R R Rawlings, et al.
The New England Journal of Medicine|April 14, 2021
Trial of Psilocybin versus Escitalopram for DepressionRobin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, et al.
Brain Communications|March 22, 2024
Brain dynamics predictive of response to psilocybin for treatment-resistant depressionJakub Vohryzek, Joana Cabral, Louis-David Lord, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 27, 2002
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomographyAnne Lingford-Hughes, Susan P Hume, Adrian Feeney, et al.
Frontiers in Psychology|June 23, 2025
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studiesWilliam Roseby, Hannes Kettner, Leor Roseman, et al.
The Journal of Clinical Psychiatry|July 4, 2001
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and AnxietyJ C Ballenger, J R Davidson, Y Lecrubier, et al.
Journal of Psychopharmacology (Oxford, England)|May 11, 2011
Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxietyJayne E Bailey, Andreas Papadopoulos, Alison Diaper, et al.
Pageof 79

Showing results (631-640 of 790) with videos related to

Sort By:
Pageof 79
Human Brain Mapping|April 9, 2025
The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic StateClayton R Coleman, Kenneth Shinozuka, Robert Tromm, et al.
Drug and Alcohol Dependence|September 7, 2001
beta-carboline binding to imidazoline receptorsS M Husbands, R A Glennon, S Gorgerat, et al.
Addiction Biology|January 7, 2016
The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient settingF D Law, J E Bailey, D S Allen, et al.
The American Journal of Psychiatry|January 1, 1997
Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjectsD T George, C Benkelfat, R R Rawlings, et al.
The New England Journal of Medicine|April 14, 2021
Trial of Psilocybin versus Escitalopram for DepressionRobin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, et al.
Brain Communications|March 22, 2024
Brain dynamics predictive of response to psilocybin for treatment-resistant depressionJakub Vohryzek, Joana Cabral, Louis-David Lord, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 27, 2002
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomographyAnne Lingford-Hughes, Susan P Hume, Adrian Feeney, et al.
Frontiers in Psychology|June 23, 2025
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studiesWilliam Roseby, Hannes Kettner, Leor Roseman, et al.
The Journal of Clinical Psychiatry|July 4, 2001
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and AnxietyJ C Ballenger, J R Davidson, Y Lecrubier, et al.
Journal of Psychopharmacology (Oxford, England)|May 11, 2011
Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxietyJayne E Bailey, Andreas Papadopoulos, Alison Diaper, et al.
Pageof 79